Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status

MEK inhibition is potentially valuable in targeting KRAS-mutant non-small cell lung cancer (NSCLC). Here, we analyzed whether concomitant LKB1 mutation alters sensitivity to the MEK inhibitor selumetinib, and whether the metabolism drug phenformin can enhance the therapeutic effect of selumetinib in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jun, Nannapaneni, Sreenivas, Wang, Dongsheng, Liu, Fakeng, Wang, Xu, Jin, Rui, Liu, Xiuju, Rahman, Mohammad Aminur, Peng, Xianghong, Qian, Guoqing, Chen, Zhuo G., Wong, Kwok-Kin, Khuri, Fadlo R., Zhou, Wei, Shin, Dong M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601710/
https://www.ncbi.nlm.nih.gov/pubmed/28938614
http://dx.doi.org/10.18632/oncotarget.19779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601710/
https://www.ncbi.nlm.nih.gov/pubmed/28938614
http://dx.doi.org/10.18632/oncotarget.19779

Ejemplares similares